Detailed information for compound 254522
Basic information
Technical information
- TDR Targets ID: 254522
- Name: (2S)-3-(4-hydroxyphenyl)-2-[[1-[[(2S)-3-pheny l-2-sulfanylpropanoyl]amino]cyclopentanecarbo nyl]amino]propanoic acid
- MW: 456.555 | Formula: C24H28N2O5S
-
H donors: 4
H acceptors: 5
LogP: 3.49
Rotable bonds: 11
Rule of 5 violations (Lipinski): 1 - SMILES: OC(=O)[C@@H](NC(=O)C1(CCCC1)NC(=O)[C@H](Cc1ccccc1)S)Cc1ccc(cc1)O
- InChi: 1S/C24H28N2O5S/c27-18-10-8-17(9-11-18)14-19(22(29)30)25-23(31)24(12-4-5-13-24)26-21(28)20(32)15-16-6-2-1-3-7-16/h1-3,6-11,19-20,27,32H,4-5,12-15H2,(H,25,31)(H,26,28)(H,29,30)/t19-,20-/m0/s1
- InChiKey: QKYIOXOQENXWBI-PMACEKPBSA-N
Network
Hover on a compound node to display the structore
Synonyms
- (2S)-3-(4-hydroxyphenyl)-2-[[1-[[(2S)-3-phenyl-2-sulfanyl-propanoyl]amino]cyclopentanecarbonyl]amino]propanoic acid
- (2S)-3-(4-hydroxyphenyl)-2-[[[1-[[(2S)-2-mercapto-1-oxo-3-phenylpropyl]amino]cyclopentyl]-oxomethyl]amino]propanoic acid
- (2S)-3-(4-hydroxyphenyl)-2-[[1-[[(2S)-3-phenyl-2-sulfanyl-propanoyl]amino]cyclopentyl]carbonylamino]propanoic acid
- (2S)-3-(4-hydroxyphenyl)-2-[[1-[[(2S)-2-mercapto-3-phenyl-propanoyl]amino]cyclopentanecarbonyl]amino]propionic acid
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Rattus norvegicus | Neprilysin | Starlite/ChEMBL | References |
| Oryctolagus cuniculus | Angiotensin-converting enzyme | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Onchocerca volvulus | Neprilysin | 750 aa | 713 aa | 34.1 % | |
| Schistosoma mansoni | family M13 non-peptidase homologue (M13 family) | Neprilysin | 750 aa | 778 aa | 20.2 % |
| Onchocerca volvulus | Neprilysin | 750 aa | 682 aa | 31.1 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.042 | 0.5051 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0086 | 0.003 | 0.003 |
| Loa Loa (eye worm) | hypothetical protein | 0.0114 | 0.0448 | 0.0448 |
| Loa Loa (eye worm) | PAN domain-containing protein | 0.0088 | 0.0062 | 0.0062 |
| Schistosoma mansoni | hypothetical protein | 0.042 | 0.5051 | 1 |
| Leishmania major | hypothetical protein, conserved | 0.042 | 0.5051 | 0.5 |
| Brugia malayi | Peptidase family M13 containing protein | 0.0114 | 0.0448 | 0.0388 |
| Trypanosoma cruzi | hypothetical protein, conserved | 0.042 | 0.5051 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0088 | 0.0062 | 0.0062 |
| Loa Loa (eye worm) | PAN domain-containing protein | 0.0088 | 0.0062 | 0.0062 |
| Onchocerca volvulus | 0.042 | 0.5051 | 1 | |
| Mycobacterium ulcerans | zinc metalloprotease | 0.0114 | 0.0448 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0088 | 0.0062 | 0.0062 |
| Loa Loa (eye worm) | hypothetical protein | 0.0086 | 0.003 | 0.003 |
| Echinococcus multilocularis | tissue type plasminogen activator | 0.042 | 0.5051 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0086 | 0.003 | 0.003 |
| Loa Loa (eye worm) | hypothetical protein | 0.0088 | 0.0062 | 0.0062 |
| Echinococcus granulosus | tissue type plasminogen activator | 0.042 | 0.5051 | 1 |
| Toxoplasma gondii | peptidase family M13 protein | 0.0114 | 0.0448 | 0.0774 |
| Loa Loa (eye worm) | hypothetical protein | 0.0086 | 0.003 | 0.003 |
| Loa Loa (eye worm) | hypothetical protein | 0.042 | 0.5051 | 0.5051 |
| Brugia malayi | Hypothetical zinc metalloproteinase T16A9.4 | 0.0114 | 0.0448 | 0.0388 |
| Loa Loa (eye worm) | hypothetical protein | 0.0114 | 0.0448 | 0.0448 |
| Loa Loa (eye worm) | hypothetical protein | 0.0088 | 0.0062 | 0.0062 |
| Loa Loa (eye worm) | PAN domain-containing protein | 0.0088 | 0.0062 | 0.0062 |
| Mycobacterium leprae | probable zinc metalloprotease | 0.0114 | 0.0448 | 0.5 |
| Brugia malayi | Protein kinase domain containing protein | 0.042 | 0.5051 | 0.502 |
| Loa Loa (eye worm) | hypothetical protein | 0.0114 | 0.0448 | 0.0448 |
| Toxoplasma gondii | kringle domain-containing protein | 0.042 | 0.5051 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0088 | 0.0062 | 0.0062 |
| Loa Loa (eye worm) | TK/ROR protein kinase | 0.042 | 0.5051 | 0.5051 |
| Loa Loa (eye worm) | angiotensin-converting enzyme family protein | 0.0749 | 1 | 1 |
| Mycobacterium tuberculosis | Probable zinc metalloprotease Zmp1 | 0.0114 | 0.0448 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0086 | 0.003 | 0.003 |
| Loa Loa (eye worm) | hypothetical protein | 0.0088 | 0.0062 | 0.0062 |
| Loa Loa (eye worm) | hypothetical protein | 0.0086 | 0.003 | 0.003 |
| Loa Loa (eye worm) | PAN domain-containing protein | 0.0088 | 0.0062 | 0.0062 |
| Brugia malayi | Kringle domain containing protein | 0.042 | 0.5051 | 0.502 |
| Loa Loa (eye worm) | PAN domain-containing protein | 0.0088 | 0.0062 | 0.0062 |
| Loa Loa (eye worm) | hypothetical protein | 0.0088 | 0.0062 | 0.0062 |
| Plasmodium falciparum | cysteine repeat modular protein 1 | 0.042 | 0.5051 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| IC50 (binding) | = 3 nM | Evaluation of in vitro inhibitory activity against Neutral endopeptidase | ChEMBL. | 8544178 |
| IC50 (binding) | = 3 nM | Evaluation of in vitro inhibitory activity against Neutral endopeptidase | ChEMBL. | 8544178 |
| IC50 (binding) | = 22 nM | Evaluation of in vitro inhibitory activity against Angiotensin I converting enzyme | ChEMBL. | 8544178 |
| IC50 (binding) | = 22 nM | Evaluation of in vitro inhibitory activity against Angiotensin I converting enzyme | ChEMBL. | 8544178 |
| Inhibition (functional) | = 17 % | Evaluation of plasma inhibition of Angiotensin I converting enzyme activity in conscious rat 6 hours after intravenous administration of the compound at a dose of 10 mg/kg | ChEMBL. | 8544178 |
| Inhibition (functional) | = 17 % | Evaluation of plasma inhibition of Angiotensin I converting enzyme activity in conscious rat 6 hours after intravenous administration of the compound at a dose of 10 mg/kg | ChEMBL. | 8544178 |
| Inhibition (functional) | = 43 % | Evaluation of plasma inhibition of Angiotensin I converting enzyme activity in conscious rat 4 hours after intravenous administration of the compound at a dose of 10 mg/kg | ChEMBL. | 8544178 |
| Inhibition (functional) | = 43 % | Evaluation of plasma inhibition of Angiotensin I converting enzyme activity in conscious rat 4 hours after intravenous administration of the compound at a dose of 10 mg/kg | ChEMBL. | 8544178 |
| Inhibition (functional) | = 75 % | Evaluation of plasma inhibition of Angiotensin I converting enzyme activity in conscious rat 2 hours after intravenous administration of the compound at a dose of 10 mg/kg | ChEMBL. | 8544178 |
| Inhibition (functional) | = 75 % | Evaluation of plasma inhibition of Angiotensin I converting enzyme activity in conscious rat 2 hours after intravenous administration of the compound at a dose of 10 mg/kg | ChEMBL. | 8544178 |
| Inhibition (functional) | = 86 % | Evaluation of plasma inhibition of Angiotensin I converting enzyme activity in conscious rat 1 hour after intravenous administration of the compound at a dose of 10 mg/kg | ChEMBL. | 8544178 |
| Inhibition (functional) | = 86 % | Evaluation of plasma inhibition of Angiotensin I converting enzyme activity in conscious rat 1 hour after intravenous administration of the compound at a dose of 10 mg/kg | ChEMBL. | 8544178 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL147702
- PubChem: 10575777
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.